IFN-α, is a type I interferon that promotes dendritic cell maturation, B cell activation, and autoantibody production. By blocking IFN-α, rontalizumab aims to dampen the chronic interferon-driven inflammation characteristic of SLE, potentially improving clinical outcomes in patients with high interferon pathway activity.